UniProt Q14145
Kelch-like ECH-associated protein 1 (Q14145)
Kelch-like ECH-associated protein 1 (UniProt Q14145): 164 experimental structures on GenesisL1, 41 ligands bound, 217 pockets. Binding sites, pockets, druggability and 3D structures in GL1X.
- UniProt
- Q14145
- Protein
- Kelch-like ECH-associated protein 1
- Experimental structures
- 164
- Predicted models
- 0
- Ligands
- 41
- Pockets
- 217 · 51 records with a druggable one
Structures
164 records of Q14145 in the MolNFT archive: 164 experimental, 0 predicted.
| Entry | Title | Method | Chains | Ligands | Pockets |
|---|---|---|---|---|---|
| 1U6D | Crystal structure of the Kelch domain of human Keap1 | x-ray diffraction | X | — | — |
| 1U6D | Crystal structure of the kelch domain of human KEAP1 | x-ray diffraction | X | — | — |
| 1ZGK | 1.35 angstrom structure of the Kelch domain of Keap1 | x-ray diffraction | A | — | — |
| 1ZGK | 1.35 ångström structure of the kelch domain of KEAP1 | x-ray diffraction | A | — | — |
| 3VNG | Crystal Structure of Keap1 in Complex with Synthetic Small Molecular based on a co-crystallization | x-ray diffraction | A | — | — |
| 3VNG | Crystal structure of KEAP1 in complex with synthetic small molecular based on a co-crystallization | x-ray diffraction | A | — | — |
| 3VNH | Crystal Structure of Keap1 Soaked with Synthetic Small Molecular | x-ray diffraction | A | — | — |
| 3VNH | Crystal structure of KEAP1 soaked with synthetic small molecular | x-ray diffraction | A | — | — |
| 3ZGC | crystal structure of the KEAP1-NEH2 complex | x-ray diffraction | A, B | — | — |
| 3ZGC | Crystal structure of the KEAP1-NEH2 complex | x-ray diffraction | A, B | — | — |
| 3ZGD | crystal structure of a KEAP1 mutant | x-ray diffraction | A, B | — | — |
| 3ZGD | Crystal structure of a KEAP1 mutant | x-ray diffraction | A, B | — | — |
| 4CXI | BTB domain of KEAP1 | x-ray diffraction | A | — | — |
| 4CXI | Btb domain of KEAP1 | x-ray diffraction | A | — | — |
| 4CXJ | BTB domain of KEAP1 C151W mutant | x-ray diffraction | A | — | — |
| 4CXJ | Btb domain of KEAP1 C151W mutant | x-ray diffraction | A | — | — |
| 4CXT | BTB domain of KEAP1 in complex with CDDO | x-ray diffraction | A | — | — |
| 4CXT | Btb domain of KEAP1 in complex with cddo | x-ray diffraction | A | — | — |
| 4IFJ | Crystal Structures of apo Keap1, Keap1-peptide, and Keap1-compound complexes | x-ray diffraction | A | — | — |
| 4IFJ | Crystal structures of apo KEAP1, KEAP1-peptide, and KEAP1-compound complexes | x-ray diffraction | A | — | — |
| 4IFL | Crystal Structures of apo Keap1, Keap1-peptide, and Keap1-compound complexes | x-ray diffraction | X | — | — |
| 4IFL | Crystal structures of apo KEAP1, KEAP1-peptide, and KEAP1-compound complexes | x-ray diffraction | X | — | — |
| 4IFN | Crystal Structures of apo Keap1, Keap1-peptide, and Keap1-compound complexes | x-ray diffraction | X | — | — |
| 4IFN | Crystal structures of apo KEAP1, KEAP1-peptide, and KEAP1-compound complexes | x-ray diffraction | X | — | — |
| 4IN4 | Crystal structure of cpd 15 bound to Keap1 Kelch domain | x-ray diffraction | A, B, C | — | — |
| 4IN4 | Crystal structure of cpd 15 bound to KEAP1 kelch domain | x-ray diffraction | A, B, C | — | — |
| 4IQK | Crystal structure of cpd 16 bound to Keap1 Kelch domain | x-ray diffraction | A | — | — |
| 4IQK | Crystal structure of cpd 16 bound to KEAP1 kelch domain | x-ray diffraction | A | — | — |
| 4L7B | Structure of keap1 kelch domain with (1S,2R)-2-{[(1S)-1-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)met… | x-ray diffraction | A, B | — | — |
| 4L7B | Structure of KEAP1 kelch domain with (1S,2R)-2-{[(1S)-1-[(1,3-dioxo-1… | x-ray diffraction | A, B | — | — |
| 4L7C | Structure of keap1 kelch domain with 2-{[(1S)-2-{[(1R,2S)-2-(1H-tetrazol-5-yl)cyclohexyl]carbonyl}-1… | x-ray diffraction | A, B, C | — | — |
| 4L7C | Structure of KEAP1 kelch domain with 2-{[(1S)-2-{[(1R,2S)-2-(1H… | x-ray diffraction | A, B, C | — | — |
| 4L7D | Structure of keap1 kelch domain with (1S,2R)-2-{[(1S)-5-methyl-1-[(1-oxo-1,3-dihydro-2H-isoindol-2-y… | x-ray diffraction | A, B, C | — | — |
| 4L7D | Structure of KEAP1 kelch domain with (1S,2R)-2-{[(1S)-5-methyl-1-[(1… | x-ray diffraction | A, B, C | — | — |
| 4N1B | STRUCTURE OF KEAP1 KELCH DOMAIN WITH(1S,2R)-2-[(1S)-1-[(1-oxo-2,3-dihydro-1H-isoindol-2-Yl)methyl]-1… | x-ray diffraction | A, B, C | — | — |
| 4N1B | Structure of KEAP1 kelch domain WITH(1S,2R)-2-[(1S)-1-[(1-oxo-2,3… | x-ray diffraction | A, B, C | — | — |
| 4XMB | Crystal structure of 2,2'-(naphthalene-1,4-diylbis(((4-methoxyphenyl)sulfonyl)azanediyl))diacetamide… | x-ray diffraction | A | — | — |
| 4XMB | Crystal structure of 2,2'-(naphthalene-1,4-DIYLBIS(((4-methoxyphenyl)… | x-ray diffraction | A | — | — |
| 5DAD | Crystal Structure of Human KEAP1 BTB Domain in Complex with Small Molecule TX64014 | x-ray diffraction | A | TX6 | — |
| 5DAD | Crystal structure of human KEAP1 btb domain in complex with small molecule TX64014 | x-ray diffraction | A | — | — |
| 5DAF | Crystal Structure of Human KEAP1 BTB Domain in Complex with Small Molecule TX64063 | x-ray diffraction | A | 58E | — |
| 5DAF | Crystal structure of human KEAP1 btb domain in complex with small molecule TX64063 | x-ray diffraction | A | — | — |
| 5F72 | De novo design and crystallographic validation of antibodies targeting a pre-selected epitope | x-ray diffraction | K, C | — | 5 (best 0.84) |
| 5F72 | De novo design and crystallographic validation of antibodies targeting a pre-selected epitope | x-ray diffraction | K, C | — | — |
| 5GIT | BTB domain of KEAP1 in complex with XX3 | x-ray diffraction | A | XXT | — |
| 5GIT | Btb domain of KEAP1 in complex with XX3 | x-ray diffraction | A | — | — |
| 5NLB | Crystal structure of human CUL3 N-terminal domain bound to KEAP1 BTB and 3-box | x-ray diffraction | A | — | — |
| 5NLB | Crystal structure of human CUL3 N-terminal domain bound to KEAP1 btb and 3-box | x-ray diffraction | A | — | — |
| 5WFL | Kelch domain of human Keap1 in open unliganded conformation | x-ray diffraction | A, B | SO4 | 5 (best 0.75) |
| 5WFL | Kelch domain of human KEAP1 in open unliganded conformation | x-ray diffraction | A, B | SO4 | — |
| 5WFV | Kelch domain of human Keap1 bound to Nrf2 ETGE peptide | x-ray diffraction | A, B | SO4 | 4 (best 0.77) |
| 5WFV | Kelch domain of human KEAP1 bound to NRF2 etge peptide | x-ray diffraction | A, B | SO4 | — |
| 5WG1 | Kelch domain of human Keap1 bound to mutant Nrf2 EAGE peptide | x-ray diffraction | A, B | SO4 | — |
| 5WG1 | Kelch domain of human KEAP1 bound to mutant NRF2 eage peptide | x-ray diffraction | A, B | SO4 | — |
| 5WHL | Kelch domain of human Keap1 bound to inhibitory small molecule fragment: hydroxyphenyl propionic… | x-ray diffraction | A, B | HPP, SO4 | 5 (best 0.77) |
| 5WHL | Kelch domain of human KEAP1 bound to inhibitory small molecule fragment: hydroxyphenyl propionic… | x-ray diffraction | A, B | HPP, SO4 | — |
| 5WHO | Kelch domain of human Keap1 bound to small molecule inhibitor fragment… | x-ray diffraction | B, A | SO4, AO7 | — |
| 5WHO | Kelch domain of human KEAP1 bound to small molecule inhibitor fragment… | x-ray diffraction | B, A | SO4, AO7 | — |
| 5WIY | Kelch domain of human Keap1 bound to small molecule inhibitor fragment… | x-ray diffraction | A, B | SO4, 1XM | 4 (best 0.74) |
| 5WIY | Kelch domain of human KEAP1 bound to small molecule inhibitor fragment… | x-ray diffraction | A, B | SO4, 1XM | — |
104 records more on the page itself.
Ligands
- SO4 · Sulfate ion · in 25 records
- NA · Sodium ion · in 16 records
- CL · Chloride ion · in 14 records
- NH2 · Amino group · in 4 records
- Q5Y · N-[(4-methoxyphenyl)sulfonyl]-N-(4-{[(4-methoxyphenyl) sulfonyl]amino}naphthalen-1-yl)glycine · in 3 records
- 08A · (3S)-3-[2-(benzenecarbonyl)-5-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl]-3-(1-ethyl-4-methyl-1H-benzotriazol-5-yl)propanoic acid · in 2 records
- 1XM · 4-amino-1,7-dihydro-6H-pyrazolo[3,4-d]pyrimidine-6-thione · in 2 records
- 92I · (3S,5S,8R)-8-[[(2S)-1-ethanoylpyrrolidin-2-yl]carbonylamino]-N,N-dimethyl-3,7,11-tris(oxidanylidene)-10-oxa-3$l^{4}-thia-6-azabicyclo[10.4.0]hexadeca-1(16),12,14-triene-5-carboxamide · in 2 records
- 9IB · 3-[(5S,8R)-5-(dimethylcarbamoyl)-8-[[(2S)-1-ethanoylpyrrolidin-2-yl]carbonylamino]-7,11-bis(oxidanylidene)-10-oxa-3-thia-6-azabicyclo[10.4.0]hexadeca-1(16),12,14-trien-16-yl]benzoic acid · in 2 records
- AO7 · 4-oxo-4H-1-benzopyran-2-carboxylic acid · in 2 records
- D8N · ~{N}-[4-[(5~{R})-4,5-dihydro-1,2-oxazol-5-yl]phenyl]ethanamide · in 2 records
- GCI · N-[4-[(2-azanyl-2-oxidanylidene-ethyl)-[4-[(2-azanyl-2-oxidanylidene-ethyl)-(4-methoxyphenyl)sulfonyl-amino]naphthalen-1-yl]sulfamoyl]phenyl]-3-morpholin-4-yl-propanamide · in 2 records
- GDJ · N-[4-[(2-azanyl-2-oxidanylidene-ethyl)-[4-[(2-azanyl-2-oxidanylidene-ethyl)-(4-methoxyphenyl)sulfonyl-amino]naphthalen-1-yl]sulfamoyl]phenyl]-2-(4-ethylpiperazin-1-yl)ethanamide · in 2 records
- GFD · 2-[(4-aminophenyl)sulfonyl-[4-[(2-azanyl-2-oxidanylidene-ethyl)-(4-methoxyphenyl)sulfonyl-amino]naphthalen-1-yl]amino]ethanamide · in 2 records
- GX8 · 2-[[4-[2-hydroxy-2-oxoethyl-(4-methoxyphenyl)sulfonyl-amino]-3-phenylmethoxy-phenyl]-(4-methoxyphenyl) sulfonyl-amino]ethanoic acid · in 2 records
- HPP · Hydroxyphenyl propionic acid · in 2 records
- LQ8 · (1~{S},2~{R})-2-[[(1~{S})-1-[[1,3-bis(oxidanylidene) isoindol-2-yl]methyl]-5-(2-hydroxyethyloxy)-3,4-dihydro-1~{H}-isoquinolin-2-yl]carbonyl]cyclohexane-1-carboxylic acid · in 2 records
- Q9E · (5S,8R)-8-[[(2S)-1-ethanoylpyrrolidin-2-yl]carbonylamino]-N,N-dimethyl-7,11-bis(oxidanylidene)-10-oxa-3-thia-6-azabicyclo[10.4.0]hexadeca-1(16),12,14-triene-5-carboxamide · in 2 records
- 58E · (5aS,6S,9aS)-7-hydroxy-2,6,9a-trimethyl-3-(pyridin-3-yl)-4,5,5a,6,9,9a-hexahydro-2H-benzo[g]indazole-8-carbonitrile · in 1 record
- 8ZL · (5S,8R)-N,N-dimethyl-8-[[(2S)-1-[4-(methylamino)-4-oxidanylidene-butanoyl]pyrrolidin-2-yl]carbonylamino]-7,11-bis(oxidanylidene)-10-oxa-3-thia-6-azabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide · in 1 record
- 91M · (5S,8R)-16-(2,1,3-benzoxadiazol-4-yl)-8-[[(2S)-1-ethanoylpyrrolidin-2-yl]carbonylamino]-N,N-dimethyl-7, 11-bis(oxidanylidene)-10-oxa-3-thia-6-azabicyclo[10.4.0]hexadeca-1(16),12,14-triene-5-carboxamide · in 1 record
- 9J3 · 4-ethoxy-4-oxobutanoic acid · in 1 record
- 9P0 · 4-[(5S,8R)-5-(dimethylcarbamoyl)-8-[[(2S)-1-ethanoylpyrrolidin-2-yl]carbonylamino]-7,11-bis(oxidanylidene)-10-oxa-3-thia-6-azabicyclo[10.4.0]hexadeca-1(16),12,14-trien-16-yl]benzoic acid · in 1 record
- A1BCT · 1-{(3S)-3-[3-(4-amino-1,3,5-triazin-2-yl)-5-chlorophenyl]morpholin-4-yl}propan-1-one · in 1 record
- A1H67 · (3R)-4-[4-(2-chlorophenyl)sulfonyl-1,3-thiazol-5-yl]-1,3-dimethyl-piperazin-2-one · in 1 record
- A1H7T · 2-[[5-[(2~{R})-2,4-dimethyl-3-oxidanylidene-piperazin-1-yl]-2,3-dihydro-1,3-thiazol-4-yl]sulfonyl]benzenecarbonitrile · in 1 record
- A1LVC · (2~{R},3~{S})-3-[[(2~{S})-2-[4-[(3-ethoxypyridin-2-yl)methyl]phenyl]-2-fluoranyl-ethanoyl]amino]-2-methyl-3-(4-methylphenyl)propanoic acid · in 1 record
- ACA · 6-aminohexanoic acid · in 1 record
- DAV · Delta-amino valeric acid · in 1 record
- DYW · (2~{S})-1-[(2~{S})-2-azanyl-4-oxidanyl-4-oxidanylidene-butanoyl]pyrrolidine-2-carboxylic acid · in 1 record
Elsewhere
GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.